Optima Health Valuation
Is J3N undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of J3N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: J3N (€1.9) is trading below our estimate of fair value (€3.22)
Significantly Below Fair Value: J3N is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for J3N?
Key metric: As J3N is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is J3N's PS Ratio? | |
|---|---|
| PS Ratio | 1.3x |
| Sales | UK£110.89m |
| Market Cap | UK£140.27m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.6x |
| Enterprise Value/EBITDA | 13.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does J3N's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.1x | ||
M3V MeVis Medical Solutions | 2.6x | n/a | €45.1m |
AJ91 DocCheck | 0.8x | n/a | €42.1m |
COP CompuGroup Medical SE KGaA | 0.6x | 1.4% | €726.9m |
NXU Nexus | 4.5x | 9.8% | €1.2b |
J3N Optima Health | 1.3x | 1.7% | €140.3m |
Price-To-Sales vs Peers: J3N is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (2.1x).
Price to Sales Ratio vs Industry
How does J3N's PS Ratio compare vs other companies in the European Healthcare Services Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: J3N is good value based on its Price-To-Sales Ratio (1.3x) compared to the European Healthcare Services industry average (2.2x).
Price to Sales Ratio vs Fair Ratio
What is J3N's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.3x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate J3N's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
LNA Santé
€244.4m
Engages in the management and operation of health establishments.
2N3
€23.25
7D
-5.5%
1Y
18.9%
Shandong Weigao Group Medical Polymer
HK$20.1b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.52
7D
-8.8%
1Y
-37.3%
Top Glove Corporation Bhd
RM 7.8b
An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.
5OU
RM 0.98
7D
0.5%
1Y
-82.5%